ERBB2 and neoplasm: In addition, we demonstrated an enhanced lysis of HER2-expressing tumor cells by the combination of trastuzumab and PBL in PDAC cell lines established from primary cells (stage G1–G3, e.g., PancTu-I and Panc1) as well as in OC cells such as cisplatin-resistant SK-OV-3 cells and primary tumor cells OC1 and OC11.